drugset
drugset / Trial / NCT04164758

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758 ↗

Phase 2 Terminated 11 enrolled ACADIA Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a pilot study to explore the effects of pimavanserin and low-dose quetiapine in subjects with Parkinson's disease with neuropsychiatric symptoms.

Timeline

Start
2019-10-23
Primary completion
2020-09-25
Completion
2020-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 34 mg Oral
Comparator Quetiapine Small molecule 25 mg Oral
Comparator Quetiapine Small molecule 50 mg Oral
Comparator Quetiapine Small molecule 100 mg Oral

Indications

Parkinson disease